Twist Bioscience to Expand Commercial Capabilities with Factory of the Future
December 22 2020 - 7:00AM
Business Wire
-- State-of-the-Art Site Near Portland, Oregon
Expected to More than Double Manufacturing Capacity, Increase Speed
of Production and Enable Enhanced Product Offerings --
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced plans to expand its
manufacturing and commercial capabilities with the addition of the
“Factory of the Future” just outside of Portland, Oregon in
Wilsonville. The 110,000-square-foot facility is expected to become
operational in 2022 and potentially bring up to 400 jobs to the
region over several years.
“The Portland area is an established technology hub relatively
close in proximity to our headquarters with a growing number of
biotechnology companies, providing access to talent and advanced
manufacturing to increase the speed of production and deliver
products to our customers faster,” said Emily M. Leproust, Ph.D.,
CEO and co-founder of Twist Bioscience.
Leproust continued, “We are expanding our customer base and
ramping production of our products at an exceptional rate. The
Factory of the Future allows us to support the increasing needs of
our customers as they scale globally and plan for aggressive growth
into synthetic biology and biopharma market segments we cannot
serve today.”
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein may be deemed to be forward-looking statements, including,
but not limited to: statements regarding the time frame in which
the facility will become operational; and the expected benefits to
Twist Bioscience, its customers and the Portland region from the
establishment of the facility, including without limitation
expected improvements to total addressable market and value
proposition and future product innovation. These statements reflect
the current beliefs and expectations of management made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements involve known
and unknown risks, uncertainties, and other important factors that
may cause Twist Bioscience’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the risk that the facility does not become
operational on the expected time frame or at all due to
construction or other delays, as well as the risks and
uncertainties set forth in Twist Bioscience’s Annual Report on Form
10-K filed with the Securities and Exchange Commission on November
27, 2020 and subsequent filings with the SEC. risks and
uncertainties set forth in Twist Bioscience’s Annual Report on Form
10-K filed with the Securities and Exchange Commission on November
27, 2020 and subsequent filings with the SEC. Any of these risks
and uncertainties could materially and adversely affect Twist
Bioscience’s results of operations, which would, in turn, have a
significant and adverse impact on Twist Bioscience’s stock price.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and Twist Bioscience specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201222005179/en/
Angela Bitting Twist Bioscience SVP, Corporate Affairs 925-
202-6211 abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2024 to Aug 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Aug 2023 to Aug 2024